Drugs and Medicine - Clinical Research Informer

Ethnopharmacology: traditional medicine and modern drug discovery

Pharmaceutical Technology

APRIL 24, 2023

Traditional medicine refers to the knowledge, skills and practices that indigenous and different cultures use to maintain health, encompassing forms such as herbal medicine, Traditional Chinese Medicine (TCM) and acupuncture. Without the knowledge from ethnopharmacological work, many drugs would not be available today.

Medicine

Medicine Drugs Production Research

Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures

Drug Patent Watch

DECEMBER 9, 2024

This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. But what exactly is pharmacognosy, and how does it relate to the complex world of drug patents? They then isolate and identify compounds with potential medicinal properties.

Medicine

Medicine Drugs Production Development

CARsgen and Huadong Medicine to commercialise CT053 in mainland China

Pharmaceutical Technology

JANUARY 16, 2023

CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. Under the collaboration, Huadong Medicine will have the exclusive right to commercialise CARsgen’s CT053 in mainland China.

Medicine

Medicine Gene Therapy Production Gene

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

These microscopic tunnels are a goldmine for new medicines

Bio Pharma Dive

JUNE 27, 2024

A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.

Medicine

Medicine Drugs Research

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. But its impact goes far beyond research.

Clinical Trials

FDA approves new ALS medicine in precedent-setting decision

Bio Pharma Dive

APRIL 25, 2023

Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.

FDA Approval

FDA Approval Medicine Protein Marketing

Drug patents protect pharma profits. Track when they’ll expire here.

Bio Pharma Dive

MAY 8, 2024

Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

Drugs

Drugs Medicine

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

Bio Pharma Dive

SEPTEMBER 4, 2024

Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Drugs

Drugs Medicine

J&J-backed startup launches with $100M to build better brain drugs

Bio Pharma Dive

MARCH 7, 2023

Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.

Drugs

Drugs Protein Medicine

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

Bio Pharma Dive

JULY 15, 2024

Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.

Medicine

Medicine Trials Drugs

What to make of Eisai and Biogen’s latest Alzheimer’s drug data

Bio Pharma Dive

NOVEMBER 29, 2022

At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits.

Doctor

Doctor Doctors Drugs Clinical Trials

Dantari emerges with a new way to make cancer drug conjugates

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs

Drugs Antibody Medicine Development

AstraZeneca extends run of trial successes with breast cancer drug results

Bio Pharma Dive

OCTOBER 26, 2022

On the heels of a major approval for Enhertu, the pharma reported positive results for two experimental drugs in settings where rival medicines from Roche and Sanofi recently failed.

Drugs

Drugs Trials Medicine

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

Bio Pharma Dive

APRIL 18, 2024

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company has acquired a portfolio of medicines it aims to test in combination.

Drugs

Drugs Medicine

ALS drugs from Denali, Calico come up short, marking more failures for Healey trial

Bio Pharma Dive

JANUARY 7, 2025

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Life Science

Life Science Trials Drugs Medicine

Versant startup sets out to make a new type of obesity drug

Bio Pharma Dive

NOVEMBER 21, 2024

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.

Drugs

Drugs Medicine Development

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Bio Pharma Dive

JANUARY 6, 2023

The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.

Drugs

Drugs Medicine

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

Bio Pharma Dive

JANUARY 11, 2023

Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort.

FDA Approval

FDA Approval Drugs Sales Medicine

Ipsen drug for rare liver disease approved by FDA

Bio Pharma Dive

JUNE 11, 2024

The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.

Drugs

Drugs Medicine

Medicare names first 10 drugs for price negotiations

Bio Pharma Dive

AUGUST 29, 2023

The list includes the top-selling blood thinners Eliquis and Xarelto, as well as the arthritis drug Enbrel and heart failure medicine Entresto.

Drugs

Drugs Medicine

Amylyx’s ALS drug could face rejection in Europe

Bio Pharma Dive

MAY 30, 2023

The biotech said a committee advising the European Medicines Agency is “trending” toward issuing a negative opinion of its drug Relyvrio, which was approved in the U.S. last year.

Drugs

Drugs Medicine

CMS removes 7 drugs from list marked for price hike penalties

Bio Pharma Dive

MARCH 31, 2023

After revising its calculations, CMS removed Gilead’s cancer cell therapies Yescarta and Tecartus, as well as 5 other medicines, from the first set of drugs subject to rebates under a provision of the IRA.

Drugs

Drugs Medicine

Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

Bio Pharma Dive

FEBRUARY 22, 2024

The startup’s Series C round will support a clinical-stage drug the company thinks could address some of the weaknesses of other KRAS-targeting medicines.

Drugs

Drugs Medicine

Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex

Bio Pharma Dive

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs

Drugs Medicine Marketing

Panel recommends programme for uniform high standard drug regulation nationwide

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2025

A Parliamentary Panel has recommended implementation of a comprehensive, nationwide and phased Medicines Regulatory Maturity Enhancement Programme on the lines of World Health Organisation’s (WHO) vaccine benchmarking process to ensure a consistently high standard of drug regulation across the country.

Regulation

Regulation Drugs Vaccination Vaccine

Lisata receives orphan drug designation for pancreatic cancer therapy

Pharmaceutical Technology

OCTOBER 18, 2023

Lisata has received orphan drug designation from the EMA's Committee for Orphan Medicinal Products for LSTA1 to treat pancreatic cancer.

Drugs

Drugs Medicine Production

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

Bio Pharma Dive

JUNE 12, 2024

Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

Drugs

Drugs Gene Medicine

Roche, following setbacks, turns to its next Alzheimer’s drug

Bio Pharma Dive

MARCH 11, 2024

Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.

Drugs

Drugs Medicine

Takeda wagers up to $6B on Nimbus’ TYK2 drug

Bio Pharma Dive

DECEMBER 13, 2022

The Japanese pharma is paying $4 billion upfront, and potentially $2 billion more, for a medicine Nimbus claims can top Bristol Myers’ recently approved psoriasis drug Sotyktu.

Drugs

Drugs Medicine

BrainStorm files ALS drug application over FDA protest

Bio Pharma Dive

MARCH 27, 2023

The medicine, a personalized stem cell treatment, will be reviewed by an FDA advisory committee sometime in the future, the company said.

Medicine

Medicine Drugs

Novo Nordisk follows Lilly in sharply cutting price of insulin drugs

Bio Pharma Dive

MARCH 14, 2023

Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

Insulin

Insulin Drugs Branding Medicine

Psychiatry drugs finally have pharma’s attention. Can they keep it?

Bio Pharma Dive

APRIL 8, 2024

But many development hurdles still stand in the way of new medicines for the brain. Recent biotech company acquisitions have put emerging schizophrenia treatments in focus.

Medicine

Medicine Drugs Development

Structure boosted by early data for experimental obesity drug

Bio Pharma Dive

SEPTEMBER 29, 2023

Shares in the biotech surged on Phase 1 trial results for an oral GLP-1 drug Structure is developing, reflecting investor enthusiasm for the weight loss medicines.

Drugs

Drugs Medicine Trials Development

Boehringer, Sosei Heptares team up in schizophrenia drug deal

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs

Drugs Protein Medicine Development

Astellas to acquire eye drug developer Iveric Bio for $5.9B

Bio Pharma Dive

MAY 1, 2023

The deal is a sizable bet on an experimental geographic atrophy drug now under review that could compete with a medicine from Apellis Pharmaceuticals.

Drugs

Drugs Development Medicine

Pfizer says hemophilia drug succeeded in Phase 3 study

Bio Pharma Dive

MAY 30, 2023

The drug, called marstacimab, outperformed factor treatment in the study, and wasn’t associated with the kind of safety signals that have dogged other medicines in its class.

Drugs

Drugs Medicine

Sanofi drug, acquired from a startup, shows early potential in MS

Bio Pharma Dive

MAY 31, 2023

The medicine, licensed from biotech ImmuNext in 2017, is one of two later-stage MS drug prospects in the French drugmaker’s portfolio.

Licensing

Licensing Licensing Drugs Medicine

FDA advisers back Amylyx ALS drug, reversing earlier position

Bio Pharma Dive

SEPTEMBER 8, 2022

Committee members voted 7-2 in support of the experimental medicine, which is under a closely watched FDA review. A decision on approval is expected by the end of the month.

Medicine

Medicine Drugs

FDA rejects two China-developed cancer drugs

Bio Pharma Dive

MAY 2, 2022

The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine.

Development

Development Regulation Manufacturing Drugs

Intellia presses forward with new results for pioneering CRISPR drug

Bio Pharma Dive

FEBRUARY 28, 2022

The findings build on early evidence that gene editing inside the body could safely and effectively treat disease, and suggest the effects of Intellia's medicine might last.

Gene Editing

Gene Editing Gene Medicine Drugs

Moderna founder unveils new drug company focused on a different kind of RNA

Bio Pharma Dive

NOVEMBER 9, 2021

The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA

RNA Medicine Drugs Research

Synlogic’s SYNB1934 receives orphan drug status from US FDA

Pharmaceutical Technology

MAY 10, 2023

Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease. The orally administered, non-systemically absorbed drug candidate SYNB1934 has been designed for reducing blood phenylalanine (Phe) levels in PKU patients.

Genetic Engineering

Genetic Engineering Drugs Engineer Genetics

Wave to seek approval of Duchenne drug after mid-stage study data

Bio Pharma Dive

MARCH 26, 2025

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Medicine

Medicine Drugs

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.

Development

Development Drugs Pharma Companies Life Science

Ethnopharmacology: traditional medicine and modern drug discovery

Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures

Webinars

Trending Sources

CARsgen and Huadong Medicine to commercialise CT053 in mainland China

Webinars

These microscopic tunnels are a goldmine for new medicines

Bridging Innovation & Patient Care: The Growing Role of AI

FDA approves new ALS medicine in precedent-setting decision

Drug patents protect pharma profits. Track when they’ll expire here.

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

J&J-backed startup launches with $100M to build better brain drugs

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

What to make of Eisai and Biogen’s latest Alzheimer’s drug data

Dantari emerges with a new way to make cancer drug conjugates

AstraZeneca extends run of trial successes with breast cancer drug results

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

ALS drugs from Denali, Calico come up short, marking more failures for Healey trial

Versant startup sets out to make a new type of obesity drug

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

Ipsen drug for rare liver disease approved by FDA

Medicare names first 10 drugs for price negotiations

Amylyx’s ALS drug could face rejection in Europe

CMS removes 7 drugs from list marked for price hike penalties

Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex

Panel recommends programme for uniform high standard drug regulation nationwide

Lisata receives orphan drug designation for pancreatic cancer therapy

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

Roche, following setbacks, turns to its next Alzheimer’s drug

Takeda wagers up to $6B on Nimbus’ TYK2 drug

BrainStorm files ALS drug application over FDA protest

Novo Nordisk follows Lilly in sharply cutting price of insulin drugs

Psychiatry drugs finally have pharma’s attention. Can they keep it?

Structure boosted by early data for experimental obesity drug

Boehringer, Sosei Heptares team up in schizophrenia drug deal

Astellas to acquire eye drug developer Iveric Bio for $5.9B

Pfizer says hemophilia drug succeeded in Phase 3 study

Sanofi drug, acquired from a startup, shows early potential in MS

FDA advisers back Amylyx ALS drug, reversing earlier position

FDA rejects two China-developed cancer drugs

Intellia presses forward with new results for pioneering CRISPR drug

Moderna founder unveils new drug company focused on a different kind of RNA

Synlogic’s SYNB1934 receives orphan drug status from US FDA

Wave to seek approval of Duchenne drug after mid-stage study data

Cloud robotics labs are accelerating drug discovery and development

Stay Connected